Our study and previous studies found that the onset of VEGFR2-TKI (YN968D1) response and relapse is similar to that observed with VEGFR2 mAb (DC101) (22, 25), supporting the notion that VEGFR2-TKI predominantly blocks the VEGFR2 pathway in breast cancer. This evidence concerns the gene KDR and breast cancer.